Open source software with more than 1 million monthly downloads was compromised after a threat actor exploited a ...

Closed upsized initial public offering in February 2026, raising $381 million in gross proceeds Completed enrollment of the TeLuRide-005 Phase 2 trial of EIK1001 in first-line treatment of stage 4 non ...

MILLBRAE, Calif., March 30, 2026 (GLOBE NEWSWIRE)-- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to ...

Eikon Therapeutics, Inc. (Nasdaq: EIKN), a California-based, late-stage biotechnology company, visits the Nasdaq MarketSite in Times Square. Eikon is led by executive and clinical teams behind the ...

Spotify is changing how its APIs work in Developer Mode, its layer that lets developers test their third-party applications using the audio platform’s APIs. The changes include a mandatory premium ...

Biotechnology companies going public this week are signaling a resurgence for initial public offerings and venture-capital investment in the sector this year. Biotechs Eikon Therapeutics and ...

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Eikon Therapeutics increased the ...

Eikon Therapeutics shares were down 6%, at $16.90, in the stock's first day of trade on the Nasdaq Global Select Market. Shares of the clinical-stage biopharmaceutical company began trading midday ...

Feb 5 (Reuters) - Drug developer Eikon Therapeutics , headed by Merck veteran Roger Perlmutter, was valued at about $860.3 million after its shares opened 5.3% below their offer price in their Nasdaq ...

Despite progress made in cancer immunotherapy, some patients don’t respond to these treatments or they stop responding after a period of time. Eikon Therapeutics’ lead drug candidate could address ...